MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
The Motley Fool
July 29, 2011
Sean Williams
Another Day, Another Loss For Cell Therapeutics Cell Therapeutics is giving shareholders that sinking feeling. mark for My Articles similar articles
The Motley Fool
September 17, 2010
Luke Timmerman
Cell Therapeutics OK'd to Sell Shares to Stay Alive Is the company being straight with shareholders? mark for My Articles similar articles
The Motley Fool
December 31, 2011
David Williamson
2011 Review: Cell Therapeutics After starting the year at a split-adjusted $2.22 a share, Cell Therapeutics stock lost almost 50% of its value by the end of December, closing at $1.16. How did we get here? mark for My Articles similar articles
The Motley Fool
June 15, 2011
Brian Orelli
Investors Need a Peephole Into FDA Offices Cell Therapeutics is gung ho about its resubmission, but investors only get one side of the story. mark for My Articles similar articles
The Motley Fool
June 15, 2005
Brian Gorman
Cell Therapeutics' Gamble The biotech company's struggles are far from over. Without an approved drug on the market or the certainty of FDA clearance, the firm won't have an easy time finding investors. mark for My Articles similar articles
The Motley Fool
September 28, 2011
Brian Orelli
One Step Closer to an FDA Decision Cell Therapeutics is still risky, though. mark for My Articles similar articles
The Motley Fool
May 27, 2011
Brian Orelli
What Kind of Phase 2 Drug Can You Get for $5 Million? Cell Therapeutics issues a press release saying the company has identified a potential acquisition opportunity that is a phase II drug candidate. mark for My Articles similar articles
The Motley Fool
May 4, 2011
Brian Orelli
Cell Therapeutics: Denied but Not Rejected Cell Therapeutics' ball may be headed for the end zone, but the FDA has an eight-foot free safety ready to bat it down. mark for My Articles similar articles
The Motley Fool
September 18, 2006
Brian Lawler
Cell Therapeutics' New Mate The biopharmaceutical company removes some uncertainty by teaming up with Novartis. Investors, take note. mark for My Articles similar articles
The Motley Fool
July 1, 2011
Brian Orelli
What Will Cell Therapeutics Do With Your Money? Unfortunately the answer is probably, "buying a drug." mark for My Articles similar articles
Registered Rep.
February 1, 2005
Bob Hirschfeld
Healing Investments New lung cancer drugs mean good news in both the doctor's office and on Wall Street. mark for My Articles similar articles
BusinessWeek
November 20, 2006
Arlene Weintraub
Is Cell Therapeutics In Remission? Battered biotech Cell Therapeutics' controversial CEO has won over Novartis, but investors are wary. mark for My Articles similar articles
The Motley Fool
September 15, 2010
Brian Orelli
Cell Therapeutics Goes for Broke If Cell Therapeutics can't get new funding soon, long-term consequences may be the least of its worries; time on the clock looks to be running out. mark for My Articles similar articles
The Motley Fool
October 14, 2010
Matt Koppenheffer
Cell Therapeutics' Shares Popped: What You Need to Know Shares of biopharma specialist Cell Therapeutics leapt more than 16% today on huge volume. mark for My Articles similar articles
BusinessWeek
July 23, 2007
Gene G. Marcial
At Ziopharm, Arsenic Is Not So Toxic Ziopharm uses arsenic that is organic. It's stock is rated a buy. mark for My Articles similar articles
BusinessWeek
July 12, 2004
David Henry
That Old Electric Surge International Rectifier's business is growing where it counts most, in high-profit-margin products that use its special electrical device technologies. mark for My Articles similar articles
The Motley Fool
July 20, 2010
Jordan DiPietro
Cell Therapeutics Finds a New Home The company signs a long-term agreement with an Italian manufacturer for a lymphoma treatment. mark for My Articles similar articles
The Motley Fool
July 26, 2010
Tom Gardner
A Disaster for Shareholders Two biotechnology stocks not worth the trouble. mark for My Articles similar articles
AskMen.com
Dave Golokhov
Cell Phones And Cancer With so much money in the cell phone industry, it looks like straight answers regarding the risks will be hard to come by. mark for My Articles similar articles
BusinessWeek
November 10, 2003
Arlene Weintraub
Biotech Startups: Take Your Time Until products are close to approval, the public shouldn't share the risk mark for My Articles similar articles
InternetNews
March 23, 2009
Michelle Megna
Cell Phone Users Cutting Back in Harsh Economy The mobile industry will have to increasingly rely on smartphone sales as cell phone usage falls out of favor in souring economy. mark for My Articles similar articles
InternetNews
September 17, 2010
Study: Mobile Phone Users Largely Ignore Apps Pew Research Center study finds majority of cell phone owners don't bother using any of the apps embedded on them. mark for My Articles similar articles
BusinessWeek
April 4, 2005
Gene G. Marcial
Ballooning Bank Deposits At E*Trade Shares of E*Trade, a provider of online brokerage and banking services, have languished this year because investors have been disappointed at weak trading and stiff competition. But investors should focus on its banking, which is growing fast. mark for My Articles similar articles
BusinessWeek
February 16, 2004
Catherine Arnst
Medicare vs. Cancer Patients Refusing to reimburse off-label treatment is far from the best way to cut costs. mark for My Articles similar articles
Chemistry World
October 31, 2012
Ian Le Guillou
A cell for a cell If you ever need to isolate a single bacterial cell, why not build it a prison cell? This is the approach that colleagues from Sandia National Laboratories, US, have taken. Using multi-photon lithography, they can construct four walls and a roof around a single cell in just over a minute. mark for My Articles similar articles